Role of Epidermal Growth Factor Receptor (EGFR) and Its Ligands in Kidney Inflammation and Damage
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Chronic kidney disease (CKD) is characterized by persistent inflammation and progressive fibrosis, ultimately leading to end-stage renal disease. Although many studies have investigated the factors involved in the progressive deterioration of renal function, current therapeutic strategies only delay disease progression, leaving an unmet need for effective therapeutic interventions that target the cause behind the inflammatory process and could slow down or reverse the development and progression of CKD. Epidermal growth factor receptor (EGFR) (ERBB1), a membrane tyrosine kinase receptor expressed in the kidney, is activated after renal damage, and preclinical studies have evidenced its potential as a therapeutic target in CKD therapy. To date, seven official EGFR ligands have been described, including epidermal growth factor (EGF) (canonical ligand), transforming growth factor-α, heparin-binding epidermal growth factor, amphiregulin, betacellulin, epiregulin, and epigen. Recently, the connective tissue growth factor (CTGF/CCN2) has been described as a novel EGFR ligand. The direct activation of EGFR by its ligands can exert different cellular responses, depending on the specific ligand, tissue, and pathological condition. Among all EGFR ligands, CTGF/CCN2 is of special relevance in CKD. This growth factor, by binding to EGFR and downstream signaling pathway activation, regulates renal inflammation, cell growth, and fibrosis. EGFR can also be “transactivated” by extracellular stimuli, including several key factors involved in renal disease, such as angiotensin II, transforming growth factor beta (TGFB), and other cytokines, including members of the tumor necrosis factor superfamily, showing another important mechanism involved in renal pathology. The aim of this review is to summarize the contribution of EGFR pathway activation in experimental kidney damage, with special attention to the regulation of the inflammatory response and the role of some EGFR ligands in this process. Better insights in EGFR signaling in renal disease could improve our current knowledge of renal pathology contributing to therapeutic strategies for CKD development and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“However, the response to gefitinib and erlotinib did not improve survival and improvements were only observed in those patients with mutations in EGFR [261, 262].”
BackgroundUntangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974 · cited 1×
“Only ERBB1/EGFR, ERBB3, and ERBB4 are able to bind ligands, an obligatory process for activation of the tyrosine kinase domain and intracellular signaling [226, 227].”
BackgroundScreening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373 · cited 1×
“CRIPTO1 is critically important in early embryogenesis, maintenance of stem cells, and the progression of some types of cancer [172].”
BackgroundCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904 · cited 1×
“Among the developed antibodies, cetuximab stands out, which improved the survival rates in patients with lung cancer and colorectal cancer in combination with chemotherapy [264, 265].”
BackgroundBIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447 · cited 1×
“Another newly developed inhibitor is afatinib, with dual specificity against EGFR/ ERBB1 and HER2/ERBB2 [263].”
BackgroundInnate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus
Monticelli (2011) · PubMed · doi:10.1031/ni.2131 · Cited by 1,286
A Special Population of Regulatory T Cells Potentiates Muscle Repair
Burzyn, D., Kuswanto, W., Kolodin, D., Shadrach, J. L., Cerletti, M., Jang, Y., Sefik, E., Tan, T. G., Wagers, A. J., Benoist, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.054 · Cited by 1,234 · cited 2×
“Emerging evidence shows that AREG plays a critical role in restoring tissue integrity after infection or inflammation [145–148] and induces tolerance by promoting the restoration of tissue integrity after damage associated with acute or chronic inflammation [149, 150].”
BackgroundA heparin-binding growth factor secreted by macrophage-like cells that is related to EGF
Higashiyama, S., Abraham, J. A., Miller, J., Fiddes, J. C., & Klagsbrun, M. (1991) · Science · doi:10.1126/science.1840698 · Cited by 1,127
Biscardi, J. S., Maa, M.-C., Tice, D. A., Cox, M. E., Leu, T.-H., & Parsons, S. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.12.8335 · Cited by 649
The epidermal growth factor receptor ligands at a glance
Schneider, M. R., & Wolf, E. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21635 · Cited by 447 · cited 1×
“EPGN is present in many tissues such as the testes, heart, and liver and is characterized as a lowaffinity ligand [165, 166].”
BackgroundKireeva, M. L., Mo, F.-E., Yang, G. P., & Lau, L. F. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1326 · Cited by 341 · cited 2×
“Several EGFR ligands contain amino-terminal heparin-binding domains (HBEGF domains), including HBEGF, AR, and CTGF [87, 88].”
BackgroundIsobe, T., Okuyama, T., Toyoda, H., Komurasaki, T., Uchida, D., Takayama, Y., & Hanada, K. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.13.7495 · Cited by 269
The CCN family: A new class of inflammation modulators?
Kular, L., Pakradouni, J., Kitabgi, P., Laurent, M., & Martinerie, C. (2011) · Biochimie · doi:10.1016/j.biochi.2010.11.010 · Cited by 183 · cited 1×
“CTGF is a chemotactic factor for immune cells, including mononuclear cells [209], and induces cell adhesion and migration [210].”
BackgroundPerugorria, M. J., Latasa, M. U., Nicou, A., Cartagena‐Lirola, H., Castillo, J., Goñi, S., Vespasiani‐Gentilucci, U., Zagami, M. G., Lotersztajn, S., Prieto, J., et al. (2008) · Hepatology · doi:10.1002/hep.22437 · Cited by 151
Rodriguez-Vita, J., Ruiz-Ortega, M., Rupérez, M., Esteban, V., Sanchez-López, E., Plaza, J. J., & Egido, J. (2005) · Circulation Research · doi:10.1161/01.res.0000174614.74469.83 · Cited by 119 · cited 1×
“Initial studies demonstrated the role of CTGF as a mediator of the profibrotic action of TGFB [200] and other factors involved in renal damage, such as Ang II [201] or endothelin1 [202].”
BackgroundSelf-citationDisease-association analysis of an inflammation-related feedback loop
Murakami, M., Harada, M., Kamimura, D., Ogura, H., Okuyama, Y., Kumai, N., Okuyama, A., Singh, R., Jiang, J.-J., Atsumi, T., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.01.028 · Cited by 110 · cited 2×
“In this pathology, EPR inhibition suppresses the development of experimental autoimmune arthritis [161].”
BackgroundActivation of Nrf2 in keratinocytes causes chloracne (MADISH)-like skin disease in mice
Schäfer, M., Willrodt, A., Kurinna, S., Link, A. S., Farwanah, H., Geusau, A., Gruber, F., Sorg, O., Huebner, A. J., Roop, D. R., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303281 · Cited by 98 · cited 1×
“The EPGN transgenic overexpression during embryonic development induces sebaceous gland hyperplasia [167], and the activation of NRF2 causes sebaceous gland enlargement in an EPGN-dependent manner [168].”
BackgroundDey, M., Baldys, A., Sumter, D. B., Göőz, P., Luttrell, L. M., Raymond, J. R., & Göőz, M. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168054 · Cited by 40 · cited 1×
“[91] reported a beneficial effect of ADAM-mediated EGFR transactivation by bradykinin, leading to a decrease of podocyte permeability.”
Background
Cited by
Targeting the progression of chronic kidney disease
Ruiz-Ortega, M., Rayego-Mateos, S., Lamas, S., Ortiz, A., & Rodrigues-Diez, R. R. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0248-y · Cited by 979
Self-citationSARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids
Jansen, J., Reimer, K. C., Nagai, J. S., Varghese, F. S., Overheul, G. J., de Beer, M., Roverts, R., Daviran, D., Fermin, L. A. S., Willemsen, B., et al. (2022) · Cell Stem Cell · doi:10.1016/j.stem.2021.12.010 · Cited by 259
Metadata
- Authors
- Rayego-Mateos, S., Rodrigues-Diez, R., Morgado-Pascual, J. L., Valentijn, F., Valdivielso, J. M., Goldschmeding, R., & Ruiz-Ortega, M.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2018-12-23
- Volume
- 2018
- Pages
- 1-22
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W2905689668
- Cited by
- 175
- References
- 19
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.